nach oben

Erschienen in:

01.03.2016 | Research Article

Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients

verfasst von: L. Ceniceros, J. Aristu, E. Castañón, C. Rolfo, J. Legaspi, A. Olarte, G. Valtueña, M. Moreno, I. Gil-Bazo

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Lung cancer is the most frequent neoplasm in humans. Surgery is considered the best therapeutic approach for stage I non-small lung cell cancer (NSCLC). However, a remarkable amount of patients are considered as inoperable. Stereotactic body radiotherapy (SBRT) has risen as an option for those patients, rendering excellent results in quality of life and survival.

Materials and methods

We analyzed clinical studies published between 2002 and 2015 which included SBRT as a treatment modality. Our own clinical series was analyzed as well. The patterns of failure following SBRT were investigated, together with the outcomes and the toxicity observed.

Results

SBRT has proven to maintain an excellent local control. The analysis showed the tumor size and the histology as determinant factors for the response to treatment.

Conclusion

According to the published evidence as well as our own experience, SBRT is a safe and feasible approach for early NSCLC. Its results may be comparable with surgery treatment.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefPubMed

Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–82.CrossRefPubMed

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (sbrt) for operable stage i non-small-cell Lung cancer: can sbrt be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81(5):1352–8.CrossRefPubMed

Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28(6):928–35.CrossRefPubMed

Joyner M, Salter BJ, Papanikolaou N, Fuss M. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol. 2006;45(7):802–7.CrossRefPubMed

Oshiro Y, Aruga T, Tsuboi K, Marino K, Hara R, Sanayama Y, et al. Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol. 2010;186(5):274–9.CrossRefPubMed

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.CrossRefPubMed

Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011;6(12):2036–43.CrossRefPubMed

Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):967–71.CrossRefPubMed

10.

Takahashi W, Yamashita H, Omori M, Kitaguchi M, Shibata-Kobayashi S, Sakumi A, et al. The feasibility and efficacy of stereotactic body radiotherapy for centrally-located lung tumors. Anticancer Res. 2013;33(11):4959–64.PubMed

11.

Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 2012;7(9):1394–9.CrossRefPubMed

12.

Blanco R, Maestu I, de la Torre MG, Cassinello A, Nuñez I. A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol. 2015;26(3):451–63.CrossRefPubMed

13.

Pallis AG, Gridelli C, Van Meerbeeck JP, Greillier L, Wedding U, Lacombe D, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol. 2010;21(4):692–706.CrossRefPubMed

14.

Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94(1):1–11.CrossRefPubMed

15.

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290–6.CrossRefPubMed

16.

Nyman J, Johansson K, Hultén U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer—mature results for medically inoperable patients. Lung Cancer. 2006;51(1):97–103.CrossRefPubMed

17.

McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non–small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010–5.CrossRefPubMed

18.

Soliman H, Cheung P, Yeung L, Poon I, Balogh J, Barbera L, et al. Accelerated hypofractionated radiotherapy for early-stage non-small-cell lung cancer: Long-term results. Int J Radiat Oncol Biol Phys. 2011;79(2):459–65.CrossRefPubMed

19.

Atallah S, Cho BCJ, Allibhai Z, Taremi M, Giuliani M, Le LW, et al. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89(3):532–8.CrossRefPubMed

20.

Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85(3):429–34.CrossRefPubMed

21.

Hiraoka M, Nagata Y. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the Japanese experience. Int J Clin Oncol. 2004;9:352–5.CrossRefPubMed

22.

Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM. Stereotactic body radiation therapy for non-small cell lung cancer Tumors greater than 5 cm: safety and efficacy. Int J Radiat Oncol Biol Phys. 2015;92(2):325–31.CrossRefPubMed

23.

Kong F, Zhao J, Wang J, Faivre-Finn C. Radiation dose effect in locally advanced non-small cell lung cancer. J Thorac Dis. 2014;6(4):336–47.PubMedCentralPubMed

24.

Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I non small cell lung carcinoma. Cancer. 2004;101(7):1623–31.CrossRefPubMed

25.

Takeda A, Sanuki N, Kunieda E, Ohashi T, Oku Y, Takeda T, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys. 2009;73(2):442–8.CrossRefPubMed

26.

Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys. 2014;88(5):1092–9.PubMedCentralCrossRefPubMed

27.

Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847–54.PubMedCentralCrossRefPubMed

28.

Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41:1–11.CrossRefPubMed

29.

Cheung PCF, Yeung LTF, Basrur V, Ung YC, Balogh J, Danjoux CE. Accelerated hypofractionation for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54(4):1014–23.CrossRefPubMed

30.

Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Ciammella P, Franco P, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer. 2010;68(1):72–7.CrossRefPubMed

31.

Casutt A, Bouchaab H, Beigelman-Aubry C, Bourhis J, Lovis A, Matzinger O. Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis. Br J Radiol. 2015;88(1049):20140687.CrossRefPubMed

32.

Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63(5):1427–31.CrossRefPubMed

33.

Kimura K, Tomita N, Shimizu A, Sato Y, Makita C, Kodaira T. A case of severe hemoptysis after stereotactic body radiotherapy for peripherally located stage I non-small cell lung cancer. Jpn J Radiol. 2015;33(6):370–4.CrossRefPubMed

34.

Zimmermann FB, Geinitz H, Schill S, Grosu A, Schratzenstaller U, Molls M, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer. 2005;48(1):107–14.CrossRefPubMed

35.

Inoue T, Shimizu S, Onimaru R, Takeda A, Onishi H, Nagata Y, et al. Clinical outcomes of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer on radiologic examination. Int J Radiat Oncol Biol Phys. 2009;75(3):683–7.CrossRefPubMed

36.

Videtic GMM, Stephans K, Reddy C, Gajdos S, Kolar M, Clouser E, et al. Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys. 2010;77(2):344–9.CrossRefPubMed

37.

Haidar YM, Rahn DA 3rd, Nath S, Song W, Bazhenova L, Makani S, et al. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis. 2014;8(1):3–12.CrossRefPubMed

38.

Crabtree T, Puri V, Timmerman R, Fernando H, Bradley J, Decker PA, et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg. 2013;145(3):692–9.CrossRefPubMed

39.

Ottlakan A, Martucci N, Rocco G. Is surgery still the best management option for early stage NSCLC? Transl Lung Cancer Res. 2014;3(3):159.PubMedCentralPubMed

40.

Crabtree TD, Puri V, Robinson C, Bradley J, Broderick S, Patterson GA, et al. Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy. J Thorac Cardiovasc Surg. 2014;147(4):1183–91.PubMedCentralCrossRefPubMed

41.

Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage i non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90(3):603–11.CrossRefPubMed

42.

Uzel EK, Abacıoğlu U. Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? Balkan Med J. 2015;32(1):8.PubMedCentralPubMed

43.

Daly ME, Beckett LA, Chen AM. Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol. 2014;4(4):240–6.PubMedCentralCrossRefPubMed

44.

Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)—can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012;102(3):335–42.CrossRefPubMed

45.

Collins BT, Erickson K, Reichner CA, Collins SP, Gagnon GJ, Dieterich S, et al. Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Radiat Oncol. 2007;2:39.PubMedCentralCrossRefPubMed

46.

Brown WT, Wu X, Fayad F, Fowler JF, Amendola BE, García S, et al. CyberKnife radiosurgery for stage I lung cancer: results at 36 months. Clin Lung Cancer. 2007;84(8):88–92.

47.

Collins BT, Vahdat S, Erickson K, Collins SP, Suy S, Yu X, et al. Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J Hematol Oncol. 2009;2:1.PubMedCentralCrossRefPubMed

48.

Chen H, Lohr F, Fritz P, Wenz F, Dobler B, Lorenz F, et al. Stereotactic, single-dose irradiation of lung tumors: a comparison of absolute dose and dose distribution between pencil beam and Monte Carlo algorithms based on actual patient CT scans. Int J Radiat Oncol Biol Phys. 2010;78(3):955–63.CrossRefPubMed

49.

Takahashi W, Yamashita H, Saotome N, Iwai Y, Sakumi A, Haga A, et al. Evaluation of heterogeneity dose distributions for stereotactic radiotherapy (SRT): comparison of commercially available Monte Carlo dose calculation with other algorithms. Radiat Oncol. 2012;7:20.PubMedCentralCrossRefPubMed

50.

Latifi K, Oliver J, Baker R, Dilling TJ, Stevens CW, Kim J, et al. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm. Int J Radiat Oncol Biol Phys. 2014;88(5):1108–13.CrossRefPubMed

Titel: Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients
verfasst von: L. Ceniceros
J. Aristu
E. Castañón
C. Rolfo
J. Legaspi
A. Olarte
G. Valtueña
M. Moreno
I. Gil-Bazo
Publikationsdatum: 01.03.2016
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 3/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1361-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients

Abstract

Introduction

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

The expression and function of Frizzled-7 in human renal cell carcinoma

Central nervous system niche involvement in the leukemia

Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis

Decreased expression of MicroRNA-200 family in human breast cancer is associated with lymph node metastasis

The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer

Methylation of ASC/TMS1 promoter is associated with poor prognosis of patients with gastric cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie